Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study

Clinical article

View More View Less
  • 1 Neurochirurgische Klinik, Universitätsklinikum Münster;
  • 2 Neurochirurgische Klinik, Ludwig-Maximilians Universität, Munich;
  • 3 Neurochirurgische Klinik, Universitätsklinikum Schleswig-Holstein Campus Kiel;
  • 4 Neurochirurgische Klinik, Universitätsklinikum Giessen;
  • 5 Institut für Neuroradiologie and
  • 6 Neurochirurgische Klinik, Johann Wolfgang Goethe Universitätsklinikum, Frankfurt am Main; and
  • 7 Medac Gesellschaft für klinische Spezialpräparate GmbH, Wedel, Germany
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

Object

Accumulating data suggest more aggressive surgery in patients with malignant glioma to improve outcome. However, extended surgery may increase morbidity. The randomized Phase III 5-aminolevulinic acid (ALA) study investigated 5-ALA–induced fluorescence as a tool for improving resections. An interim analysis demonstrated more frequent complete resections with longer progression-free survival (PFS). However, marginal differences were found regarding neurological deterioration and the frequency of additional therapies. Presently, the authors focus on the latter aspects in the final study population, and attempt to determine how safety might be affected by cytoreductive surgery.

Methods

Patients with malignant gliomas were randomized for fluorescence-guided (ALA group) or conventional white light (WL) (WL group) microsurgery. The final intent-to-treat population consisted of 176 patients in the ALA and 173 in the WL group. Primary efficacy variables were contrast-enhancing tumor on early MR imaging and 6-month PFS. Among secondary outcome measures, the National Institutes of Health Stroke Scale (NIH-SS) score and the Karnofsky Performance Scale (KPS) score were used for assessing neurological function.

Results

More frequent complete resections and improved PFS were confirmed, with higher median residual tumor volumes in the WL group (0.5 vs 0 cm3, p = 0.001). Patients in the ALA group had more frequent deterioration on the NIH-SS at 48 hours. Patients at risk were those with deficits unresponsive to steroids. No differences were found in the KPS score. Regarding outcome, a combined end point of risks and neurological deficits was attempted, which demonstrated results in patients in the ALA group to be superior to those in participants in the WL group. Interestingly, the cumulative incidence of repeat surgery was significantly reduced in ALA patients. When stratified by completeness of resection, patients with incomplete resections were quicker to deteriorate neurologically (p = 0.0036).

Conclusions

Extended resections performed using a tool such as 5-ALA–derived tumor fluorescence, carries the risk of temporary impairment of neurological function. However, risks are higher in patients with deficits unresponsive to steroids.

Abbreviations used in this paper: AE = adverse event; KPS = Karnofsky Performance Scale; NIH-SS = National Institutes of Health Stroke Scale; PFS = progression-free survival; SAE = serious AE; WL = white light; 5-ALA = 5-aminolevulinic acid.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

* See Appendix 2 for a complete list of study participants.

Address correspondence to: Walter Stummer, M.D., Department of Neurosurgery, University of Münster, Albert-Schweitzer Strasse 33, 48149 Münster, Germany. email: walter.stummer@ukmuenster.de.

Please include this information when citing this paper: published online April 16, 2010; DOI: 10.3171/2010.3.JNS097.

  • 1

    Albanese MA, , Clarke WR, , Adams HP Jr, & Woolson RF: Ensuring reliability of outcome measures in multicenter clinical trials of treatments for acute ischemic stroke. The program developed for the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Stroke 25:17461751, 1994

    • Search Google Scholar
    • Export Citation
  • 2

    Albert FK, , Forsting M, , Sartor K, , Adams HP, & Kunze S: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:4561, 1994

    • Search Google Scholar
    • Export Citation
  • 3

    Barker FG II, , Prados MD, , Chang SM, , Gutin PH, , Lamborn KR, & Larson DA, : Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84:442448, 1996

    • Search Google Scholar
    • Export Citation
  • 4

    Chang SM, , Parney IF, , McDermott M, , Barker FG II, , Schmidt MH, & Huang W, : Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. J Neurosurg 98:11751181, 2003

    • Search Google Scholar
    • Export Citation
  • 5

    Goldstein LB, , Bertels C, & Davis JN: Interrater reliability of the NIH stroke scale. Arch Neurol 46:660662, 1989

  • 6

    Kowalczuk A, , Macdonald RL, , Amidei C, , Dohrmann G III, , Erickson RK, & Hekmatpanah J, : Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41:10281038, 1997

    • Search Google Scholar
    • Export Citation
  • 7

    Lacroix M, , Abi-Said D, , Fourney DR, , Gokaslan ZL, , Shi W, & DeMonte F, : A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190198, 2001

    • Search Google Scholar
    • Export Citation
  • 8

    Macdonald DR, , Cascino TL, , Schold SC Jr, & Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:12771280, 1990

    • Search Google Scholar
    • Export Citation
  • 9

    Pichlmeier U, , Bink A, , Schackert G, & Stummer W: Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 10:10251034, 2008

    • Search Google Scholar
    • Export Citation
  • 10

    Stummer W, , Pichlmeier U, , Meinel T, , Wiestler OD, , Zanella F, & Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392401, 2006

    • Search Google Scholar
    • Export Citation
  • 11

    Stummer W, , Reulen HJ, , Meinel T, , Pichlmeier U, , Schumacher W, & Tonn JC, : Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564576, 2008

    • Search Google Scholar
    • Export Citation
  • 12

    Van den Bent MJ, , Stupp R, , Mason W, , Mirimanoff RO, , Lacombe D, & Gorlia T: Impact of the extent of resection on overall survival in newly-diagnosed glioblastoma afer chemo-irradiation with temozolamide: further analysis of EORTC study 26981. Eur J Cancer Suppl 3:134, 2005. (Abstract)

    • Search Google Scholar
    • Export Citation
  • 13

    Wityk RJ, , Pessin MS, , Kaplan RF, & Caplan LR: Serial assessment of acute stroke using the NIH Stroke Scale. Stroke 25:362365, 1994

  • 14

    Yung WK, , Albright RE, , Olson J, , Fredericks R, , Fink K, & Prados MD, : A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588593, 2000

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 705 314 13
Full Text Views 366 78 8
PDF Downloads 249 65 6
EPUB Downloads 0 0 0